{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T04:03:50Z","timestamp":1743653030642,"version":"3.40.3"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00108-024-01817-w","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T13:31:14Z","timestamp":1733319074000},"page":"433-435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lebersch\u00e4digung und Polyserositis als seltene Reaktion auf Oxcarbazepin","Liver injury and polyserositis as rare side effects of oxcarbazepine"],"prefix":"10.1007","volume":"66","author":[{"given":"Felix","family":"Brombacher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beat","family":"M\u00fcllhaupt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Licht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"1817_CR1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/hep.32689","volume":"77","author":"RJ Fontana","year":"2023","unstructured":"Fontana\u00a0RJ, Liou\u00a0I, Reuben\u00a0A et\u00a0al (2023) AASLD practice guidance on drug, herbal, and dietary supplement\u2013induced liver injury. Hepatology 77:1036. https:\/\/doi.org\/10.1002\/hep.32689","journal-title":"Hepatology"},{"key":"1817_CR2","unstructured":"Anticonvulsants (2012) LiverTox: Clinical and Research Information on Drug-Induced Liver Injury."},{"key":"1817_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1129-2377-15-34","volume":"15","author":"G Di Stefano","year":"2014","unstructured":"Di Stefano\u00a0G, La Cesa\u00a0S, Truini\u00a0A, Cruccu\u00a0G (2014) Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a\u00a0tertiary centre for neuropathic pain. J\u00a0Headache Pain 15:34. https:\/\/doi.org\/10.1186\/1129-2377-15-34","journal-title":"J Headache Pain"},{"key":"1817_CR4","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"National Institute of Diabetes and Digestive and Kidney Diseases","year":"2012","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases (2012) Roussel Uclaf Causality Assessment Method (RUCAM) in Drug Induced Liver Injury. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD)"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01817-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01817-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01817-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T06:43:28Z","timestamp":1743576208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01817-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":4,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1817"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01817-w","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"type":"print","value":"2731-7080"},{"type":"electronic","value":"2731-7099"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"25 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Brombacher und A.\u00a0Licht geben an, dass kein Interessenkonflikt besteht. B.\u00a0M\u00fcllhaupt h\u00e4lt Vertr\u00e4ge mit der Fontana Foundation, Gilead und der Fondation Etude Suisse de Cohorte Hepatite\u00a0C. Er war als Experte f\u00fcr AbbVie, MSD, Gilead, Falk und die FMH t\u00e4tig und ist Programmdirektor von LiSyM Cancer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}